Objectives: Sublingual buprenorphine, with and without naloxone, is indicated for the treatment of opioid use disorders. Although not approved for pain, some evidence suggests it may be a safe and effective alternative to conventional opioid analgesics, particularly for those with addiction problems. This study surveyed pain specialists to examine the extent to which sublingual buprenorphine was prescribed for chronic pain and explore associated clinician attitudes and characteristics.
S ublingual buprenorphine, a partial m-opioid agonist and k-opioid antagonist, is approved in the United States for the treatment of opioid use disorders. Sublingual buprenorphine has 2 formulations: with and without naloxone. The addition of naloxone, an opioid antagonist, is intended to inhibit potential opioid effects 1 thereby minimizing abuse liability and discouraging diversion without reducing the clinical efficacy. 2 Buprenorphine's high affinity with the m-opioid receptor allows for a slow dissociation, resulting in a long duration of action and mild withdrawal symptoms. 3 These properties have made the sublingual (ie, under the tongue) formulation, either tablet or film, a highly effective treatment for DSM-IV-TR opioid dependence. [4] [5] [6] [7] Since 2000, 8 physicians completing basic training on its use may apply for a DEA X-waiver to prescribe sublingual buprenorphine for opioid dependence in outpatient settings. The rationale for the X-waiver mechanism was to increase access to a safe and effective treatment using an opioid replacement treatment. Previously, opioid replacement treatment was only available in highly regulated clinics, that is, methadone. Providing treatment in the privacy of a physician's office as opposed to a maintenance program minimizes barriers to treatment and helps destigmatize treatment of opioid use disorders. 9 Research has indicated sublingual buprenorphine may be an effective treatment for reducing chronic pain symptoms. 5 Further, evidence suggests sublingual buprenorphine is currently being used by clinicians to treat chronic pain. 4, 5, 10, 11 However, although other formulations (eg, transdermal) are approved for pain management, the sublingual formulation, tablet and film, does not carry a pain indication. Experts in addiction and pain may select buprenorphine over a full agonist (albeit in divided doses) to minimize risk of abuse and diversion in addicts. 12 Little information is available regarding the extent to which off-label use of sublingual buprenorphine is occurring and under what circumstances. The purpose of this study was to examine the extent to which sublingual buprenorphine is used by pain specialists to treat chronic pain, and explore clinician attitudes and characteristics associated with its use.
MATERIALS AND METHODS

Study Sample
Prospective respondents were the 2539 members of American Pain Society, a large, multidisciplinary professional pain society. Those identified as being a medical doctor (MD or DO), physician assistant (PA), or nurse with prescriptive authority in the United States (eg, Nurse Practitioner, Clinical Nurse Specialist, Advanced Practice Nurse) were invited to participate. Members with addresses outside the United States of America and its territories were excluded. After identifying potentially eligible respondents, the survey was distributed to 1307 members between April and May, 2010. Respondents were not compensated for their participation. Sixty-one surveys were returned either as undeliverable or the potential respondent was no longer eligible (eg, no longer practicing).
Materials
The 36-item survey was developed by the authors based on a review of literature on clinicians' prescribing practices. The survey used a combination of multiple choice, fill in the blank, ranked items, and items scored on a 5-point Likert-type scale. Some items included were derived from existing surveys including questions on attitudes, 13 patient and clinician characteristics, 14 and demographics. 15, 16 The survey focused on practice characteristics and prescribing behaviors related to sublingual buprenorphine and other opioids, and was organized into the following 4 sections (in order of presentation): (1) clinician characteristics, including professional title, size of community, medical specialty, board certification, and years in practice; (2) patient characteristics, including number of patients, percentage of patients with chronic pain, and proportion of patients maintained on opioids; (3) sublingual buprenorphine-prescribing behaviors, including prescribing practices, formulations used, dosing, reasons for using, and concerns about safety and effectiveness; and (4) opioid-related attitudes and behaviors, including opioid prescribing concerns and likelihood to prescribe opioids to patients with various substance use histories. A pilot version of the survey was reviewed by experts in the areas of pain and addiction, including anesthesiologists, psychologists, and addiction psychiatrists, and feedback was incorporated into the final version.
Procedure
Because email addresses were not provided, eligible respondents received a paper copy of the survey by mail, as well as a prepaid business reply envelope and a cover letter explaining the study and requesting participation. The cover letter included the URL to an online version of the survey. Respondents were instructed to complete and return the survey anonymously. Two weeks after the initial mailing, all potential respondents received a follow-up letter reminding them about the survey. A study flow diagram is provided in Figure 1 describing the number of respondents in the final analytic data set.
Data Analysis
Data was analyzed using SPSS version 19. Descriptive statistics for survey respondents were calculated. The w 2 tests were performed to compare characteristics of sublingual buprenorphine prescribers to those of nonprescribers. The t tests examined group characteristics and differences between buprenorphine prescribers and nonprescribers' attitudes regarding buprenorphine and opioids overall. An a-level of 0.05 was used for all tests.
RESULTS
Physician Characteristics
Overall, 230 completed surveys were returned (18.5%). Except where noted, this is the sample about which results are presented. Because surveys were completed anonymously, we were unable to compare responders with nonresponders. To understand the characteristics of responders to the extent possible, we compared responders with current American Pain Society membership characteristics. A review of society membership statistics 17 indicated that respondents represented the range of clinical specialties with the society membership. Table 1 describes clinician characteristics. Respondents were distributed throughout the United States. The majority of respondents were from larger communities (52.4%), board-certified physicians with 10 to 19 years in practice (31.1%). Most had completed a fellowship (66.5%) and held an academic appointment (50.9%). Primary clinical settings were most often group practices (38.5%), academic/Veteran's Health Care (36.7%), and community hospitals (21.7%). Among respondents, 18.6% were certified by American Society of Addiction Medicine or American Board of Addiction Medicine.
Practice Characteristics and Setting
Number of patients varied greatly among clinicians (M = 1035.3, SD = 1315.2, Median = 500.0). Not surprisingly, chronic pain was a common patient symptom (79.2%); for 71.7% it was the chief complaint. Overall, 92.5% of clinicians reported prescribing opioids for the treatment of chronic pain with 53.4% of their patients maintained on opioid therapy (Table 1) .
Buprenorphine Prescribers
Overall, 45 respondents (19.7%) reported some experience using sublingual buprenorphine (with and without naloxone) to treat chronic pain. Hereafter, the term sublingual buprenorphine is used to describe both sublingual formulations, that is, with and without naloxone, except where noted. Compared with prescribers, nonprescribers were less likely to work in academic medical centers ( Table 1) . When asked to compare themselves to colleagues in their specialty, nonprescribers viewed their use of opioid analgesics for chronic pain as less frequent relative to other prescribers. Among sublingual buprenorphine prescribers, 52.3% used the buprenorphine/naloxone formulation, although 43.2% of prescribers used both formulations. Physicians reported that, during the preceding 6 months, prescriptions for sublingual buprenorphine/naloxone (M = 51.9, SD = 125.5) were greater than prescriptions for sublingual buprenorphine without naloxone (M = 8.8, SD = 21.3). A majority of sublingual buprenorphine prescribers (61.4%) had DEA X-waivers authorizing use of buprenorphine for an opioid use disorder. As shown in Table 2 , the extent of sublingual use and dosing practices was quite variable. Among prescribers, 65.0% reported that switching to buprenorphine from another opioid was their greatest challenge.
Opioid-related Practice Behaviors and Attitudes
As shown in Table 3 , no significant differences were observed between nonprescribers and prescribers of sublingual buprenorphine in terms of opioid prescribing behaviors, although 3 concerns did trend toward significance, including concerns with side effects, tolerance, and diversion. With regard to likelihood to prescribe to patients with a history of various substance use disorders, nonprescribers reported a lower likelihood of prescribing opioids to patients with prior opioid and alcohol problems. No differences were observed between nonprescribers and prescribers with regard to prescribing opioids for a patient with prior nonopioid substance use problems. Nonprescribers were also slightly less likely to prescribe any opioid to patients with current alcohol or nonopioid substance use problems than were sublingual buprenorphine prescribers.
DISCUSSION
The purpose of this study was to examine the extent to which pain specialists prescribed sublingual buprenorphine for chronic pain and to describe clinician attitudes and behaviors associated with prescribing. Among clinicians prescribing opioids, 19.7% prescribed sublingual buprenorphine, most often with naloxone. However, there was considerable variation in frequency of use. This is consistent with reports suggesting this buprenorphine formulation is thought to be a viable pain management option. 4, 5, 10, 11 Although this may not be surprising given buprenorphine's known analgesic properties, the extent of use have not been previously documented to our knowledge.
This raises the issue of why some clinicians prescribe sublingual buprenorphine for chronic pain as opposed to conventional opioid analgesics, and under what circumstances. Not surprisingly, sublingual buprenorphine prescribers viewed its use for pain more positively with respect to safety and effectiveness than nonprescribers. However, overall attitudes and behaviors toward opioid analgesics did not differentiate prescribers from nonprescribers. Both prescribers and nonprescribers of sublingual buprenorphine held similar concerns regarding prescribing opioids for chronic pain in terms of safety. This is consistent with prior reports of clinician attitudes and behaviors about opioid analgesics. 13, 14, 18 There were no differences with regard to willingness to prescribe opioid analgesics to a patient with a prior nonopioid substance use problem. These similarities indicate that clinician and the clinical environment and commonly investigated opioid analgesic-related attitudes and behaviors did not predict whether a clinician may be more likely to prescribe sublingual buprenorphine for chronic pain. It is possible that other factors, including patient characteristics beyond substance abuse, are associated with likelihood to prescribe sublingual buprenorphine. For example, it may be important to examine what role, if any, sex and other sociodemographic characteristics as well as other comorbidities, including psychiatric disorders, play in opioid prescribing.
This study is not without its limitations. The small sample size and low response rate limit the generalizability of the findings reported. The actual prevalence of sublingual buprenorphine prescribing may be different. Indeed, it is reasonable to expect that prescribing has increased since the time of this survey. Among the surveys received, there were incomplete surveys that were unusable in the data set due to a significant amount of missing information. In addition, the sample was drawn from a professional society for pain specialists. The findings might be different with the sample drawn from members of other pain societies with different perspectives on opioid therapy, or from a more general set of clinicians who prescribe opioids, for example, primary care clinicians. Finally, the data was collected before the availability of transdermal buprenorphine patches and sublingual buprenorphine/naloxone formulation as a soluble film. 19, 20 It is unknown how the availability of a transdermal formulation with a chronic pain indication may impact use of the sublingual formulations. Despite the above, this report demonstrates that sublingual buprenorphine is being prescribed off-label by pain clinicians, many of whom may not have DEA X-waivers, to treat pain in chronic pain patients. It seems unlikely that this prescribing results from efforts to circumvent the DEA X-waiver as this was a sample of pain specialists. It seems more likely that sublingual buprenorphine is being prescribed specifically for pain rather than for cooccurring chronic pain and opioid dependence. This is supported by the finding that prescribers reported no difference in their willingness to prescribe opioids for an individual with a substance use history. Although this suggests a perceived benefit, efficacy and safety of this formulation for chronic pain is uncertain.
As noted above, it is unclear why and under what circumstances clinicians elect to prescribe sublingual buprenorphine for pain. Understanding why some clinicians are more likely to prescribe buprenorphine to treat pain may identify conditions in which it may be most suitable for treating chronic pain. Such practice-based information may inform future clinical research on buprenorphine to subsequently inform clinical practice. As findings from this study did not clarify a clear rationale for its use and given the prevalence of off-label use, additional research examining its safety and effectiveness for chronic pain is warranted to assist clinicians in determining whether sublingual buprenorphine is an appropriate treatment for chronic pain. 
